SCHEMBL3412705

SCHEMBL3412705

Nc1nccc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.66
HSP90AA1 P07900 2/20 0.66
AURKA O14965 2/20 0.66
PRKACA P17612 1/20 0.66
ADORA2A P29274 1/20 0.66
PIM1 P11309 1/20 0.58
RAB9A P51151 3/20 0.57
NPC1 O15118 2/20 0.57
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 2/20 0.56
MAP4K4 O95819 1/20 0.54
HSP90AB1 P08238 1/20 0.53
PTK2 Q05397 1/20 0.53
CDK2 P24941 2/20 0.52
CCNT1 O60563 1/20 0.52
CCNA2 P20248 1/20 0.52
CDK9 P50750 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21164006 0.83 HSP90AA1 (0.70) KMOHSP90AA1AURKAPRKACAADORA2A
SCHEMBL13941206 0.83 ROCK2 (0.57) KMORAB9ANPC1MAPTMEN1
SCHEMBL13977715 0.81 JAK2 (0.63) KMOHSP90AA1AURKAPRKACAADORA2A
SCHEMBL24174772 0.80 MAP4K4 (0.54) KMONPC1MAPTMEN1KMT2A
SCHEMBL31396453 0.80 MAP4K4 (0.54) KMONPC1MAPTMEN1KMT2A
SCHEMBL8313279 0.80 HSP90AA1 (0.66) KMOHSP90AA1AURKAPRKACAADORA2A
SCHEMBL12176972 0.80 HSP90AA1 (0.92) KMOHSP90AA1AURKAPRKACAADORA2A
SCHEMBL12821368 0.80 HSP90AA1 (0.66) KMOHSP90AA1AURKAPRKACAADORA2A
SCHEMBL17200126 0.80 HSP90AA1 (0.66) KMOHSP90AA1AURKAPRKACAADORA2A
SCHEMBL474287 0.80 HSP90AA1 (0.66) KMOHSP90AA1AURKAPRKACAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109535161-A Triazolo pyrimidine analog derivative, preparation method and its application in medicine 江苏恒瑞医药股份有限公司 2019-03-29 CN disclosed
CN-105143206-B Pyrimidine -2,4- diamine derivative for treating cancer 托马斯·黑勒戴药物研究基金会 2019-01-15 CN disclosed
CN-106794181-A MTH1 inhibitors for the treatment of inflammatory and autoimmune conditions 托马斯·黑勒戴药物研究基金会 2017-05-31 CN disclosed
CN-105143206-A Pyrimidine-2,4-diamine derivatives for treatment of cancer THOMAS HELLEDAYS STIFTELSE F R MEDICINSK FORSKNING 2015-12-09 CN disclosed
US-8962834-B2 Modulators of amyloid beta HOFFMANN-LA ROCHE INC. (US) 2015-02-24 US disclosed
EP-2257541-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2013-08-14 EP disclosed
US-20130190302-A1 MODULATORS OF AMYLOID BETA HOFFMANN-LA ROCHE INC. (US) 2013-07-25 US disclosed
EP-2257541-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
US-20090215759-A1 MODULATORS FOR AMYLOID BETA HOFFMANN-LA ROCHE, INC. 2009-08-27 US disclosed
WO-2009103652-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-08-27 WO disclosed
WO-2006071035-A1 NOVEL ([1,3]THIAZOLO[5,4-B]PYRIDIN-2-YL)-2-CARBOXAMIDE DERIVATIVES LG LIFE SCIENCES, LTD. (KR) 2006-07-06 WO disclosed
US-7015216-B2 Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. (US) 2006-03-21 US disclosed
US-20040127486-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ELAN PHARMACEUTICALS, INC. 2004-07-01 US disclosed
US-6689781-B2 TREATING AN INFLAMMATORY CONDITION IN A MAMMALIAN PATIENT WHICH CONDITION IS MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. 2004-02-10 US disclosed
US-6677339-B2 S-3-(4-(3,5-DICHLOROPYRID-4-YLCARBOXAMIDO)PHENYL)-2-(4,6-DIMET HOXY-1,3,5-TRIAZIN-2-YLAMINO)PROPANOIC ACID FOR EXAMPLE; INHIBIT BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS, FOR TREATING IMMUNE OR INFLAMMATORY DISORDERS CELLTECH R & D LIMITED (GB) 2004-01-13 US disclosed
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-07-04 US disclosed
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-05-09 US disclosed
US-20020028812-A1 Phenylalanine derivatives CELLTECH CHIROSCIENCE LIMITED (GB) 2002-03-07 US disclosed
US-6348463-B1 Phenylalanine derivatives CELLTECH THERAPEUTICS LIMITED (GB) 2002-02-19 US disclosed
WO-2002008206-A1 3-AMINO-2-(4-AMINOCARBONYLOXY)PHENYL-PROPIONIC ACID DERIVATIVES AS ALPHA-4- INTEGRIN INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055509-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 KMO 2561/4885HSP90AA1 3091/4885AURKA 3077/4885
US-20020086882-A1 Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors ITGAL, ITGB4, ITGA4 KMO 3470/4885HSP90AA1 896/4885AURKA 1475/4885
US-20020028812-A1 Phenylalanine derivatives PAH, FPR1, VCAM1 KMO 616/4885HSP90AA1 2061/4885AURKA 4148/4885
US-20040127486-A1 Phenylalanine derivatives as alpha 4 integrin inhibitors ITGB4, ITGA4, ITGB3 KMO 2561/4885HSP90AA1 3091/4885AURKA 3077/4885
US-20090215759-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, APOB KMO 4286/4885HSP90AA1 832/4885AURKA 4593/4885
US-20130190302-A1 MODULATORS OF AMYLOID BETA APP, PSEN1, APOB KMO 4246/4885HSP90AA1 817/4885AURKA 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.